Results 121 to 130 of about 457,473 (371)
Frequent Klebsiella pneumoniae Urinary Tract Infections in a Patient Treated with Ruxolitinib
Antibiotics, 2019 Ruxolitinib is a targeted agent that inhibits Janus 2 Kinase and is approved for use in Polycythemia Vera and Primary Myelofibrosis. Its mechanism of action involves inhibition of cellular proliferation via the Janus kinase/signal transducer and ...
Ramy M. Hanna +3 more
doaj +1 more source
Identification of SH2-Bβ as a potent cytoplasmic activator of the tyrosine kinase Janus kinase 2 [PDF]
Proceedings of the National Academy of Sciences, 1999 Janus kinases (JAKs) are cytoplasmic tyrosine kinases critical for signaling by growth hormone (GH) and many other ligands that bind to members of the cytokine receptor superfamily. SH2-Bβ was previously identified as a JAK2-interacting protein that is tyrosyl phosphorylated in response to GH and other cytokines that activate JAK2.
L, Rui, C, Carter-Su
openaire +2 more sources
Arthritis &Rheumatology, EarlyView.Objective To evaluate the efficacy and safety of guselkumab, an interleukin‐23p19 subunit inhibitor, in participants with active psoriatic arthritis (PsA) and inadequate response (inadequate efficacy and/or intolerance) to one prior tumor necrosis factor (TNF) inhibitor.
Alexis Ogdie +12 more
wiley +1 more source
Signal transducer and activator of transcription 2 deficiency is a novel disorder of mitochondrial fission [PDF]
, 2015 Defects of mitochondrial dynamics are emerging causes of neurological disease. In two children presenting with severe neurological deterioration following viral infection we identified a novel homozygous STAT2 mutation, c.1836C4A (p.Cys612Ter), using ...
Anderson, G +14 more
core +1 more source
Arthritis &Rheumatology, Accepted Article.Background Individuals with systemic autoimmune rheumatic diseases (SARDs) are at risk for worse acute and post‐acute COVID‐19 outcomes, though whether individuals with SARDs have longer persistence of viral antigens after COVID‐19 has not been studied.
Naomi J. Patel +18 more
wiley +1 more source
T cells, the next big target in axSpA?
Arthritis &Rheumatology, Accepted Article.Axial spondyloarthritis (axSpA) is a chronic inflammatory disease characterized by complex immune dysregulation, with T cells playing a central role in its pathogenesis. In this review we synthesize current knowledge on diverse T cell subsets in axSpA, their pathogenic mechanisms, and emerging therapeutic strategies targeting these cells.
Mansi K. Aparnathi, Nigil Haroon
wiley +1 more source
CAQ Corner: Basic concepts of transplant immunology
, 2022 Liver Transplantation, EarlyView.
Amanda Cheung, Josh Levitsky
wiley +1 more source
TYK2 in Immune Responses and Treatment of Psoriasis
Journal of Inflammation Research, 2022 Lin Shang,* Jiali Cao,* Siqi Zhao, Jingya Zhang, Yanling He Department of Dermatology, Capital Medical University Affiliated Beijing Chaoyang Hospital, Beijing, People’s Republic of China*These authors contributed equally to this ...
Shang L, Cao J, Zhao S, Zhang J, He Y
doaj
The chronic myeloid leukemia stem cell: stemming the tide of persistence [PDF]
, 2017 Chronic myeloid leukaemia (CML) is caused by the acquisition of the tyrosine kinase BCR-ABL1 in a haemopoietic stem cell (HSC), transforming it into a leukaemic stem cell (LSC) that self-renews, proliferates and differentiates to give rise to a ...
Holyoake, Tessa L., Vetrie, David
core +1 more source
Efficacy, safety and cost‐effectiveness of CAR‐T therapy
British Journal of Clinical Pharmacology, EarlyView.CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher +7 more
wiley +1 more source